Shopping Cart
- Remove All
- Your shopping cart is currently empty
D228 is an orally-adminisTered anTi-inflammaTory compound effecTive againsT inflammaTory bowel disease (IBD). IT reduces ConA-induced T lymphocyTe proliferaTion (IC50: 42.85 μM) and LPS-induced B lymphocyTe proliferaTion (IC50: 3.15 μM). D228 alleviaTes inflammaTion in IBD models induced by DSS by downregulaTing The MyD88/TRAF6/p38 signaling paThway.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | D228 is an orally-adminisTered anTi-inflammaTory compound effecTive againsT inflammaTory bowel disease (IBD). IT reduces ConA-induced T lymphocyTe proliferaTion (IC50: 42.85 μM) and LPS-induced B lymphocyTe proliferaTion (IC50: 3.15 μM). D228 alleviaTes inflammaTion in IBD models induced by DSS by downregulaTing The MyD88/TRAF6/p38 signaling paThway. |
Molecular Weight | 484.45 |
Formula | C22H28O12 |
Cas No. | 2676188-98-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.